From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer.
APA
Roviello G, Catalano M, Antonuzzo L (2025). From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer.. Cancer, 131(20), e70117. https://doi.org/10.1002/cncr.70117
MLA
Roviello G, et al.. "From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer.." Cancer, vol. 131, no. 20, 2025, pp. e70117.
PMID
41066200
같은 제1저자의 인용 많은 논문 (3)
- Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. 2025;88:559-563.
- Adjuvant immunotherapy in high-risk renal cell carcinoma: Indications, limitations, and perspectives. A consensus statement from the GIOTTO uro-oncology group.
- Re: Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al. Systemic Therapy in Patients with Metastatic Castration-resistant Prostate Cancer: ASCO Guideline Update. J Clin Oncol 2025;43:2311-34.